CR20220582A - Anticuerpos anti-dectina-2 - Google Patents
Anticuerpos anti-dectina-2Info
- Publication number
- CR20220582A CR20220582A CR20220582A CR20220582A CR20220582A CR 20220582 A CR20220582 A CR 20220582A CR 20220582 A CR20220582 A CR 20220582A CR 20220582 A CR20220582 A CR 20220582A CR 20220582 A CR20220582 A CR 20220582A
- Authority
- CR
- Costa Rica
- Prior art keywords
- methods
- binding agents
- dectin
- inventive
- nucleic acids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063018952P | 2020-05-01 | 2020-05-01 | |
| PCT/US2021/030466 WO2021222894A1 (en) | 2020-05-01 | 2021-05-03 | Anti-dectin-2 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20220582A true CR20220582A (es) | 2023-01-09 |
Family
ID=76076494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20220582A CR20220582A (es) | 2020-05-01 | 2021-05-03 | Anticuerpos anti-dectina-2 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11753474B2 (https=) |
| EP (1) | EP4142881A1 (https=) |
| JP (1) | JP2023524092A (https=) |
| KR (1) | KR20230005907A (https=) |
| CN (1) | CN115461122A (https=) |
| AU (1) | AU2021262828A1 (https=) |
| BR (1) | BR112022020639A2 (https=) |
| CA (1) | CA3175576A1 (https=) |
| CL (1) | CL2022003012A1 (https=) |
| CR (1) | CR20220582A (https=) |
| IL (1) | IL297782A (https=) |
| MX (1) | MX2022013616A (https=) |
| WO (1) | WO2021222894A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3470424B1 (en) * | 2016-06-08 | 2025-04-23 | Shanghai Jiao Tong University School of Medicine | Sequence of antibody heavy chain constant region for enhancing agonist antibody activity |
| CN109843327B (zh) | 2016-07-07 | 2022-05-13 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
| WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| WO2024216089A1 (en) * | 2023-04-13 | 2024-10-17 | Bolt Biotherapeutics, Inc. | Anti-dectin-2 antibody combination therapy |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| IE913929A1 (en) | 1990-11-13 | 1992-05-20 | Immunex Corp | Bifunctional selectable fusion genes |
| AU6953394A (en) | 1993-05-21 | 1994-12-20 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| US7071171B1 (en) * | 1996-12-20 | 2006-07-04 | Board Of Regents The University Of Texas System | Unique dendritic cell-associated c-type lectins, dectin-1 and dectin-2 compositions and uses thereof |
| JP2003531149A (ja) | 2000-04-13 | 2003-10-21 | ザ・ロツクフエラー・ユニバーシテイ | 抗体由来の免疫応答の増強 |
| FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
| WO2006073921A2 (en) | 2004-12-30 | 2006-07-13 | The Rockefeller University | Compositions and methods for enhanced dendritic cell maturation and function |
| US20080286819A1 (en) | 2005-11-07 | 2008-11-20 | Ravetch Jeffrey V | Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof |
| NZ573646A (en) | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
| BR112016014952A2 (pt) | 2014-02-10 | 2017-09-19 | Merck Patent Gmbh | Inibição direcionada de tgfbeta |
| WO2015143091A1 (en) | 2014-03-19 | 2015-09-24 | Genzyme Corporation | Site-specific glycoengineering of targeting moieties |
| AU2015349878A1 (en) | 2014-11-21 | 2017-05-25 | Bristol-Myers Squibb Company | Antibodies against CD73 and uses thereof |
| WO2017117269A1 (en) * | 2015-12-29 | 2017-07-06 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for dectin-2 stimulation and cancer immunotherapy |
| CN118108847A (zh) | 2016-08-07 | 2024-05-31 | 诺华股份有限公司 | mRNA介导的免疫方法 |
| US20190336615A1 (en) | 2017-01-27 | 2019-11-07 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| CN111032087A (zh) * | 2017-06-28 | 2020-04-17 | 小利兰·斯坦福大学托管委员会 | 用于dectin-2刺激和癌症免疫治疗的方法和组合物 |
| AU2020253621A1 (en) | 2019-04-05 | 2021-11-11 | Dren Bio Management, Inc. | Methods of depleting disease causing agents via antibody targeted phagocytosis |
| CA3198102A1 (en) | 2020-10-07 | 2022-04-14 | Dren Bio, Inc. | Anti-dectin-1 antibodies and methods of use thereof |
-
2021
- 2021-05-03 KR KR1020227041317A patent/KR20230005907A/ko not_active Withdrawn
- 2021-05-03 JP JP2022566470A patent/JP2023524092A/ja active Pending
- 2021-05-03 WO PCT/US2021/030466 patent/WO2021222894A1/en not_active Ceased
- 2021-05-03 BR BR112022020639A patent/BR112022020639A2/pt unknown
- 2021-05-03 CN CN202180031853.XA patent/CN115461122A/zh active Pending
- 2021-05-03 EP EP21727697.1A patent/EP4142881A1/en active Pending
- 2021-05-03 CR CR20220582A patent/CR20220582A/es unknown
- 2021-05-03 IL IL297782A patent/IL297782A/en unknown
- 2021-05-03 CA CA3175576A patent/CA3175576A1/en active Pending
- 2021-05-03 AU AU2021262828A patent/AU2021262828A1/en active Pending
- 2021-05-03 MX MX2022013616A patent/MX2022013616A/es unknown
-
2022
- 2022-02-03 US US17/592,323 patent/US11753474B2/en active Active
- 2022-10-28 CL CL2022003012A patent/CL2022003012A1/es unknown
-
2023
- 2023-07-21 US US18/356,928 patent/US12325750B2/en active Active
-
2025
- 2025-05-13 US US19/206,753 patent/US20250270329A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL297782A (en) | 2022-12-01 |
| US12325750B2 (en) | 2025-06-10 |
| KR20230005907A (ko) | 2023-01-10 |
| US20220153849A1 (en) | 2022-05-19 |
| US20250270329A1 (en) | 2025-08-28 |
| BR112022020639A2 (pt) | 2022-11-29 |
| US20230406939A1 (en) | 2023-12-21 |
| CL2022003012A1 (es) | 2023-06-23 |
| WO2021222894A1 (en) | 2021-11-04 |
| MX2022013616A (es) | 2022-11-16 |
| AU2021262828A1 (en) | 2022-11-03 |
| EP4142881A1 (en) | 2023-03-08 |
| CN115461122A (zh) | 2022-12-09 |
| US11753474B2 (en) | 2023-09-12 |
| JP2023524092A (ja) | 2023-06-08 |
| CA3175576A1 (en) | 2021-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20220582A (es) | Anticuerpos anti-dectina-2 | |
| CY1122576T1 (el) | Ανθρωπινα αντισωματα που δεσμευουν το γονιδιο-3 ενεργοποιησης λεμφοκυτταρων (leg-3), και χρησεις εξ' αυτων | |
| PH12021551484A1 (en) | Antibodies binding to cd3 | |
| US20250206793A1 (en) | T-cell expansion method and uses | |
| MX2019000149A (es) | Proteinas de union a ligando 1 de muerte programada 1 (pd-l1) y metodos de uso de las mismas. | |
| MX2024003355A (es) | Anticuerpos anti-cd3. | |
| PE20210517A1 (es) | Anticuerpos anti-hla-g y utilizacion de los mismos | |
| MX2025012685A (es) | Anticuerpos para claudin6 y metodos para tratar el cancer | |
| EA202091219A1 (ru) | Культивирование плаценты с целью выделения экзосом | |
| IL161832A0 (en) | Pharmaceutical composition for inducing an immune response in a human or animal | |
| BR112013014265A8 (pt) | sequência de ácido nucleico isolada, receptor antígeno quimérico isolado, célula, vetor, e, métodos para estimular uma resposta imune mediada por célula t, para fornecer uma imunidade antitumoral em um mamífero, para tratar um mamífero tendo uma doença, distúrbio ou condição, para tratar um ser humano com uma doença, para gerar uma população persistente de célula t, e para expandir uma população de célula t | |
| PH12022500027A1 (en) | Antibodies binding to cd3 | |
| PH12021553254A1 (en) | Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer | |
| MX2022008925A (es) | Anticuerpos anti-pd-l1. | |
| MX2019012606A (es) | Celulas t que redirigen anticuerpos biespecificos para el tratamiento de canceres positivos a egfr. | |
| PH12022553489A1 (en) | Antibodies binding to cd3 and folr1 | |
| PE20211643A1 (es) | Inmunoterapia con peptidos restringidos a a 01 y una combinacion de peptidos contra el cancer y metodos relacionados | |
| CR20230025A (es) | Muteínas de il-10 y proteínas de fusión de las mismas referencia cruzada a solicitudes relacionadas | |
| MX2025001237A (es) | Celulas modificadas geneticamente con expresion genica reducida para mitigar el reconocimiento de celulas inmunitarias | |
| CL2021000177A1 (es) | Péptidos, combinaciones de péptidos, células y kits para el uso en la inmunoterapia contra el cáncer (divisional de la solicitud no. 201802360) | |
| WO2023015229A3 (en) | Sars-cov-2 virus-like particles | |
| Flaherty et al. | H (Tla) system: Identification of two new loci, H-31 and H-32, and alleles | |
| AU2019356414A8 (en) | Binding proteins specific for HA-1H and uses thereof | |
| WO2002068451A3 (en) | Sperm protein 17 for the diagnosis and treatment of cancer | |
| MX2024001214A (es) | Metodos y composiciones para tratar cancer. |